PDCD1 and melanoma: PD-1 blockade has been shown to have clinical efficacy in many tumors such as melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial bladder cancer, refractory Hodgkin’s lymphoma and mismatch repair deficient colorectal cancer [11–17].